Regenxbio Inc.

It’s a big year for Regenxbio. The company has a potential commercial launch of its gene therapy program for MPS II (Hunter syndrome), a Biologics License Application for its Duchenne muscular dystrop

New Phase I/II data from its Duchenne gene therapy candidate, RGX-202, have boosted Regenxbio, just as new concerns emerged about the safety of Sarepta’s established gene therapy, Elevidys (delandistr

With apparently the first death of a patient dosed with its gene therapy Elevidys (delandistrogene moxeparvovec), Sarepta incurred a significant reduction in its stock price on 18 March, as well as qu

Looking ahead to 2025, industry leaders shared their insights into the key trends and topics they expect to see. Click on topic headings to read executive predictions. The insights in this article hav